NeuroVasc secures US$34 million in funding to support clinical trials and product development

3219

NeuroVasc Technologies has entered into a strategic partnership with the Wego Group that includes US$34 million in funding to support the company’s product portfolio development and global clinical trial programme.

With a focus on novel catheter-based technologies to treat neurovascular disease, NeuroVasc has developed a comprehensive portfolio development strategy to bring differentiated tools to the interventional neuroradiology community to facilitate broader treatment options for patients suffering stroke and other neurovascular diseases, a company press release states.

The strategic partnership marks a step forward for NeuroVasc Technologies in bringing a full neurovascular platform to market. This treatment focus includes over 25.7 million cases of stroke globally each year. By 2025, the worldwide neurovascular devices market for stroke alone is expected to grow from US$2.5 billion to US$3.4 billion.

“I have worked with the team from NeuroVasc Technologies for several years during the development of their stroke technologies, and I am very impressed with the collaborative and thoughtful approach they systematically employ through the design process. This gives me full confidence in the strength of NeuroVasc’s foundation and I am looking forward to their future projects,” says Vitor Mendes-Pereira (University of Toronto, Toronto Western Hospital, Toronto, Canada).


LEAVE A REPLY

Please enter your comment!
Please enter your name here